← Back to Clinical Trials
Recruiting NCT04666402

NCT04666402 Integrated Diagnostics for Early Diagnosis of Liver Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04666402
Status Recruiting
Phase
Sponsor Manchester University NHS Foundation Trust
Condition Non-Alcoholic Fatty Liver Disease
Study Type OBSERVATIONAL
Enrollment 1,200 participants
Start Date 2020-10-21
Primary Completion 2027-03-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Blood tests for Single Nucleotide PolymorphismsFaecal microbiome analysisSerum for diagnostic biomarkers

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,200 participants in total. It began in 2020-10-21 with a primary completion date of 2027-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is an observational study that will explore the hypothesis that by combining data from patients with liver disease with novel blood biomarkers, single nucleotide polymorphism (SNP) analysis and faecal microbiome analysis. The Investigators will improve diagnosis of liver fibrosis compared to the current available diagnostic tools.

Eligibility Criteria

Inclusion Criteria: * All patients referred to Community Liver Assessment Clinic. * Male or female \> 18 years of age. * Females will be non-pregnant and non-lactating. Exclusion Criteria: * Age \< 18 years. * Pregnancy/breast-feeding. Women of childbearing potential (not \>2 years post- menopausal and/or not surgically sterilised) must have a negative blood serum pregnancy test. * Isolated bilirubinaemia. * Known pre-existing liver disease. * Acutely unwell. * Suspected malignancy.

Contact & Investigator

Central Contact

Varinder Athwal

✉ Varinder.athwal@manchester.ac.uk

📞 0161 291 5354

Principal Investigator

Varinder Athwal

PRINCIPAL INVESTIGATOR

Manchester University NHS Foundation Trust/Manchester University

Frequently Asked Questions

Who can join the NCT04666402 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Non-Alcoholic Fatty Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04666402 currently recruiting?

Yes, NCT04666402 is actively recruiting participants. Contact the research team at Varinder.athwal@manchester.ac.uk for enrollment information.

Where is the NCT04666402 trial being conducted?

This trial is being conducted at Manchester, United Kingdom.

Who is sponsoring the NCT04666402 clinical trial?

NCT04666402 is sponsored by Manchester University NHS Foundation Trust. The principal investigator is Varinder Athwal at Manchester University NHS Foundation Trust/Manchester University. The trial plans to enroll 1,200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology